Ratings Integrum AB

Equities

Market Closed - Nasdaq Stockholm Other stock markets 11:29:40 2024-05-20 am EDT			5-day change	1st Jan Change
55 ^SEK	+0.73%		+0.36%	+20.48%

May. 15	Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu	CI
May. 02	Integrum Expands Its Product Offering to the United Kingdom Market	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
The company is in a robust financial situation considering its net cash and margin position.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Historically, the company has been releasing figures that are above expectations.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1365 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
INTEGRUM AB	+20.48%	94.01M		-
STRAUMANN HOLDING AG	-10.44%	21.34B		B
SONOVA HOLDING AG	+6.12%	19.13B		A
COCHLEAR LIMITED	+7.18%	14.46B		B
DEMANT A/S	+13.18%	10.63B		B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-10.48%	2.2B		-
EMBLA MEDICAL HF.	+4.55%	1.79B		B+
MODERN DENTAL GROUP LIMITED	+20.47%	638M		-
ANGEL ROBOTICS CO., LTD.	0.00%	383M	-	-
DELCATH SYSTEMS, INC.	+93.03%	210M		-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality